

["Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin \(With or Without Sulfonylureas\) in Insulin-Naive Patients With Type 2 Diabetes \(Sustain 4\),"](#) The Lancet Diabetes & Endocrinology (2017)

["Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes,"](#) JAMA (2017)

["Efficacy And Safety Of Once-Weekly Semaglutide 2.0 Mg Versus 1.0 Mg In Patients With Type 2 Diabetes \(SUSTAIN FORTE\),"](#) The Lancet Diabetes & Endocrinology (2021)

["Efficacy and Safety of Semaglutide Compared With Liraglutide and Placebo for Weight Loss in Patients With Obesity,"](#) The Lancet (2018)

["Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG \(STEP 4\),"](#) Journal of the Endocrine Society (2021)

["Once-Weekly Semaglutide in Adults With Overweight or Obesity,"](#) The New England Journal of Medicine (2021)

["Efficacy of Subcutaneous Semaglutide Compared to Placebo for Weight Loss in Obese, Non-Diabetic Adults,"](#) International Journal of Clinical Pharmacy (2022)

["Two-Year Effects of Semaglutide in Adults With Overweight or Obesity,"](#) Nature Medicine (2022)

["Semaglutide for the Treatment of Overweight and Obesity,"](#) Diabetes, Obesity and Metabolism (2022)

["Tirzepatide Once Weekly for the Treatment of Obesity,"](#) The New England Journal of Medicine (2022)

["Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity,"](#) JAMA (2023)

["FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014,"](#) Food and Drug Administration (2021)

["Overweight & Obesity Statistics,"](#) National Institute of Diabetes and Digestive and Kidney Diseases (2021)

["GLP-1 Agonists,"](#) Cleveland Clinic (2023)

["Diabetes,"](#) World Health Organization (2023)

["Research Shows GLP-1 Receptor Agonist Drugs Are Effective but Come With Complex Concerns," UChicago Medicine \(2024\)](#)

["Medications and Conditions Associated With Weight Loss in Patients Prescribed Semaglutide Based on Real-World Data," Obesity \(2023\)](#)

["Physiology of the Weight-Loss Plateau in Response to Diet Restriction, GLP-1 Receptor Agonism, and Bariatric Surgery," Obesity \(2024\)](#)

["Maintaining Weight Loss," Johns Hopkins Medicine \(2024\)](#)

["Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States," Patient Preference and Adherence \(2020\)](#)

["Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide," Diabetes, Obesity and Metabolism \(2022\)](#)

["Novo Nordisk Bought Prescribers Over 450,000 Meals and Snacks To Promote Drugs Like Ozempic," Stat \(2023\)](#)

["Novo Nordisk Agrees to Pay \\$58 Million for Failure to Comply with FDA-Mandated Risk Program," Department of Justice \(2017\)](#)

["The Facts About the \\$35 Insulin Copay Cap in Medicare," KFF \(2024\)](#)

["Weight-Loss Drug Forecasts Jump to \\$150 Billion as Supply Grows," Reuters \(2024\)](#)

["Gut-Derived Appetite Hormones Do Not Explain Energy Intake Differences in Humans Following Low-Carbohydrate Versus Low-Fat Diets," Obesity \(2024\)](#)

["Safety of Semaglutide," Frontiers in Endocrinology \(2021\)](#)

FDA labels: [Ozempic](#), [Wegovy](#), [Zepbound](#), [Mounjaro](#)

["Putting GLP-1 RAs and Thyroid Cancer in Context," Diabetes Care \(2023\)](#)

["GLP-1 Receptor Agonists: Available Evidence Not Supporting Link With Thyroid Cancer," European Medicines Agency \(2023\)](#)

["Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer," Thyroid \(2024\)](#)

["Semaglutide and Cancer," Diabetes & Metabolic Syndrome \(2023\)](#)

["Adiposity and Risk of Thyroid Cancer," Obesity Reviews \(2015\)](#)

["The Association Between Glucagon-Like Peptide-1 Receptor Agonists \(GLP-1 Ras\) and Suicidality," Expert Opinion on Drug Safety \(2024\)](#)

["Postmarket Safety Profile of Suicide/Self-Injury for GLP-1 Receptor Agonist," European Psychiatry \(2023\)](#)

["Update on FDA's Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines Approved for Type 2 Diabetes and Obesity," FDA \(2024\)](#)

["GLP-1 Receptor Agonists and Suicidality—Caution Is Needed," JAMA Network Open \(2024\)](#)

["Associations Between the Rate, Amount, and Composition of Weight Loss as Predictors of Spontaneous Weight Regain in Adults Achieving Clinically Significant Weight Loss," Obesity Reviews \(2019\)](#)

["Bariatric Surgery-Induced Telogen Effluvium \(Bar SITE\)," Cureus \(2021\)](#)

["Weight Loss Strategies and the Risk of Skeletal Muscle Mass Loss," Nutrients \(2021\)](#)

["Excess Body Weight and Gallstone Disease," Visceral Medicine \(2021\)](#)

["Psychological Changes Following Weight Loss in Overweight and Obese Adults," PLOS One \(2014\)](#)

["Changes in Food Preferences and Ingestive Behaviors After Glucagon-Like Peptide-1 Analog Treatment," International Journal of Obesity \(2024\)](#)

["Associations of Semaglutide With Incidence and Recurrence of Alcohol Use Disorder in Real-World Population," Nature Communications \(2024\)](#)

["Trial of Lixisenatide in Early Parkinson's Disease," The New England Journal of Medicine \(2024\)](#)

["Most GLP-1 Medications Correlated with a Lower Likelihood of Anxiety and Depression Diagnoses," Epic Research \(2024\)](#)

["Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder," JAMA Network Open \(2024\)](#)

["Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases," JAMA Network Open \(2024\)](#)

["The Miracle Weight-Loss Drug Is Also a Major Budgetary Threat,"](#) The New York Times (2024)

["Estimating the Cost of New Treatments for Diabetes and Obesity,"](#) American Enterprise Institute Economic Perspectives (2023)

["Outdated Notions and Persisting Misconceptions Bar the Way to Effective Obesity Treatment,"](#) ECRI (2022)

["Widespread Misconceptions About Obesity,"](#) Canadian Family Physician (2014)

["Physiology of the Weight Reduced State,"](#) Obesity (2022)

["Persistent Metabolic Adaptation 6 Years After 'The Biggest Loser' Competition,"](#) Obesity (2016)

["Impact of Calorie Restriction on Energy Metabolism in Humans,"](#) Experimental Gerontology (2020)

["Long-Term Persistence of Hormonal Adaptations to Weight Loss,"](#) The New England Journal of Medicine (2011)

["Energy Expenditure, Metabolic Adaptation, Physical Activity and Energy Intake Following Weight Loss,"](#) European Journal of Clinical Nutrition (2024)

["Reducing Calorie Intake May Not Help You Lose Body Weight,"](#) Perspectives on Psychological Science (2017)

["Maintenance of Lost Weight and Long-Term Management of Obesity,"](#) Medical Clinics of North America (2018)